Tsu, Japan
Tsu, Japan

Mie University is a national university in Tsu, Mie, Japan. As with other 'national' universities, 'Miedai' has been a national university corporation since April 2004, when state-funded universities were partially privatised. In 2006, it was ranked 250th in the Times Higher Education Supplement list of the world's best universities.Mie University was founded on 31 May 1949 with two faculties: Liberal Arts and Agriculture. These gave way to the establishment's present composition of six faculties: Humanities, Medicine, Education, Bioresources, Engineering and Common Education - the latter dealing with cross-faculty courses such as English language teaching. Its 'Center for International Exchange' promotes international links and issues involving the global community.The institution is Mie's only 'national university', located in the city of Tsu in the Kansai region, within easy reach of Kyoto, Osaka and Nagoya. The campus is situated in the north-east of the city, close to the coast of Ise Bay. Though some students make use of nearby accommodation, larger numbers commute from the larger cities, as well as nearby towns such as Ise, Matsusaka and Toba. Wikipedia.


Time filter

Source Type

Patent
Sysmex Corporation and Mie University | Date: 2016-08-30

Disclosed is a method for analyzing a concentration state of a measurement target component in blood, the method including: obtaining a value regarding an amount of the measurement target component in a collection member in which tissue fluid has been accumulated in advance, the tissue fluid having been extracted for a predetermined extraction time period from an organism which had been subjected to a process for accelerating the extraction of the tissue fluid; obtaining a value of an area under a blood concentration time curve of the measurement target component on the basis of the value regarding the amount of the measurement target component; and calculating a value regarding a ratio of a time period during which a concentration of the measurement target component has exceeded a predetermined concentration relative to the extraction time period, on the basis of the value of the area under the blood concentration time curve.


Patent
Sysmex Corporation and Mie University | Date: 2017-03-08

Disclosed is a method for analyzing a concentration state of a measurement target component in blood, the method including: obtaining a value regarding an amount of the measurement target component in a collection member in which tissue fluid has been accumulated in advance, the tissue fluid having been extracted for a predetermined extraction time period from an organism which had been subjected to a process for accelerating the extraction of the tissue fluid; obtaining a value of an area under a blood concentration time curve of the measurement target component on the basis of the value regarding the amount of the measurement target component; and calculating a value regarding a ratio of a time period during which a concentration of the measurement target component has exceeded a predetermined concentration relative to the extraction time period, on the basis of the value of the area under the blood concentration time curve.


A transgenic mouse has a genome that includes the entire gene region of human transforming growth factor beta-1 (human TGF1) located downstream of a mouse Podocin promoter such that expression of the human TGF1 is controlled by the mouse Podocin promoter. The human TGF1 contains 7 exons and 6 introns, the human TGF1 is expressed in a kidney of the mouse as non-active TGF1 and becomes active TGF1 extracellularly, and the transgenic mouse spontaneously develops renal fibrosis.


The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof. Furthermore, found are a method for fluorescence-imaging an organ other than liver by intravenous administration, a method for evaluating biokinetics of the novel indocyanine compound, a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, utilizing the diagnostic composition including the novel indocyanine compound.


Patent
Mie University and Otsuka Pharmaceutical Factory Inc. | Date: 2017-03-22

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.


Provided are: a metal core substrate having high thermal conductivity and high electrical insulating properties; an electrophoretic deposition fluid for use in fabrication of the metal core substrate; and a method for fabricating the metal core substrate. The electrophoretic deposition fluid (28) is used during electrophoretic deposition, and contains ceramic particles (28a) for coating a metal substrate (10), and an organopolysiloxane composition which binds the ceramic particles (28a).


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-02-2016 | Award Amount: 7.69M | Year: 2017

The main objective of this proposal is to develop reliable GaN-based power devices and systems for high and medium power electronics targeting industrial and automotive applications and bringing the GaN power devices another step towards the wide usability in the energy saving environment to further tap the full potential which this new material brings along. This proposal addresses two subjects, one of which is medium power (till 10kW) GaN-on-Si based lateral HEMT structures, with special focus on high reliability, which is still a major blocking item to allow wide-spread market adoption. Hence, the impact of the GaN material quality, in combination with the device layout in view of long-term reliability will be addressed. The project aims an in-depth reliability study and qualification strategy development whereby the study of the impact of dislocations and other structural disturbances inside the materials on the long term device reliability will be specifically addressed. In addition, this proposal aims to demonstrate new device concepts with increased robustness and reliability, which will be realized, evaluated and tested thoroughly. This will demonstrate how it is possible to overcome the known limitations of the GaN on Silicon technology, like e.g. the vertical leakage, trapping phenomena and/or breakdown of lateral HEMTs. The current proposal also contains the development of novel device architecture (dual channel, substrate removal, e-mode), as well as the exploration of new material systems (Aluminum Nitride (Al-based) devices) which can also largely contribute to overcome drawbacks of the GaN on Si technology. The applicability of the novel GaN-on-Si concepts in form of an industrial inverter will be demonstrated finally, with the development of an innovative low inductance packaging system for power devices, making full benefits of the fast switching capability of GaN-based power devices.


Patent
Mie University and Otsuka Pharmaceutical Factory Inc. | Date: 2016-01-19

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.


Patent
Mie University | Date: 2016-10-19

[Problem to be solved] To provide a transgenic (TG) non-human mammal expressing human matrix metalloproteinase 2 (hMMP2) in whole body tissues, and a model animal developing COPD. [Solution] The objective is solved by development of an hMMP2-expressing TG non-human mammal characterized by the inclusion of a promoter to induce gene expression, and by the expression of the whole hMMP2 gene region placed on the downstream of the promoter that can induce systemic expression of the gene. The promoter for gene expression is preferably abeta-actin promoter, and the non-human mammal is preferably a mouse. Chronic obstructive pulmonary disease (COPD) can be induced by exposing the TG non-human mammal to inhalation of cigarette smoke extract.


Patent
Takara Bio Inc. and Mie University | Date: 2016-06-15

Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

Loading Mie University collaborators
Loading Mie University collaborators